RPRX

Royalty Pharma plc
D

RPRX

36.010
USD
-0.12
(-0.33%)
مغلق
حجم التداول
57,552
الربح لكل سهم
3
العائد الربحي
2.42
P/E
16
حجم السوق
15,566,872,731
أصول ذات صلة الأخبار المقالات

العنوان: Royalty Pharma plc

القطاع: Healthcare
الصناعة: Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.